Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency

<p>Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient, who relapsed 1 year after immunotherapy with engineered T...

Full description

Bibliographic Details
Main Authors:	Lahman, MC, Schmitt, TM, Paulson, KG, Vigneron, N, Buenrostro, D, Wagener, FD, Voillet, V, Martin, L, Gottardo, R, Bielas, J, McElrath, JM, Stirewalt, DL, Pogosova-Agadjanyan, EL, Yeung, CC, Pierce, RH, Egan, DN, Bar, M, Hendrie, PC, Kinsella, S, Vakil, A, Butler, J, Chaffee, M, Linton, J, McAfee, MS, Hunter, DS, Bleakley, M, Rongvaux, A, Van den Eynde, BJ, Chapuis, AG, Greenberg, PD
Format:	Journal article
Language:	English
Published:	American Association for the Advancement of Science 2022

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency

Similar Items